{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-162056","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2024-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.928686+00:00","generated_at":"2026-06-01T04:08:37.066665+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Mirum reports positive interim Ph2b data for volixibat in PBC and PSC","bullets":["VANTAGE PBC trial: volixibat achieved placebo-adjusted -2.32 point itch reduction (p=0.0026); 75% of patients had >50% drop in serum bile acids.","Significant fatigue improvement at week 16; no new safety signals; diarrhea (77%) mostly mild/moderate and transient; 4 SAEs (1 placebo).","VANTAGE and VISTAS PSC trials to continue with volixibat 20 mg twice daily; independent data review committee recommended continuation for PSC.","No clinically meaningful changes in liver biomarkers in PBC; sponsor remains blinded to interim results."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-162056","json":"https://secwatch.observer/filing/0001193125-24-162056.json","markdown":"https://secwatch.observer/filing/0001193125-24-162056.md","text":"https://secwatch.observer/filing/0001193125-24-162056.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000119312524162056/0001193125-24-162056-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000119312524162056/d853346d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:08:37.066665+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}